WC
JAZZ icon

Wexford Capital’s Jazz Pharmaceuticals JAZZ Stock Holding History

Wexford Capital’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-2,300
Closed -$358K – 176
2017
Q2 		$358K Buy
+2,300
New +$352K 0.03% 132
2014
Q3 		– Sell
-38,835
Closed -$5.71M – 130
2014
Q2 		$5.71M Buy
+38,835
New +$5.39M 0.43% 28
2013
Q4 		– Sell
-5,000
Closed -$460K – 245
2013
Q3 		$460K Buy
+5,000
New +$403K 0.04% 153

Other funds holding JAZZ

PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
SIG
Senator Investment Group New York $2.18B AUM 58.56% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Wexford Capital's JAZZ Position: Q3 2017 in Review

Wexford Capital sold out of Jazz Pharmaceuticals (JAZZ) in Q3 2017, closing a stake of 2,300 shares — an estimated $358K sold.

Wexford Capital first reported a position in JAZZ in Q3 2013 and held it in 3 quarters. The position peaked at $5.71M in Q2 2014. 303 funds tracked by Wall St. Rank hold JAZZ as of Q3 2017.

  • Wexford Capital reported no remaining Jazz Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Wexford Capital sold 2,300 Jazz Pharmaceuticals shares in Q3 2017, an estimated $358K.
  • Wexford Capital first reported a position in Jazz Pharmaceuticals in Q3 2013 and held it in 3 quarters.
  • Wexford Capital's Jazz Pharmaceuticals position peaked at $5.71M in Q2 2014.
  • 303 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2017.

Based on Wexford Capital's 13F filing for Q3 2017, filed 13 Nov 2017.